Where There is Hope: A Qualitative Study Examining Patients' Adherence to Multi-Drug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan

Hdl Handle:
http://hdl.handle.net/10144/618343
Title:
Where There is Hope: A Qualitative Study Examining Patients' Adherence to Multi-Drug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan
Authors:
Horter, S; Stringer, B; Greig, J; Amangeldiev, A; Tillashaikhov, MN; Parpieva, N; Tigay, Z; du Cros, P
Journal:
BMC Infectious Diseases
Abstract:
Treatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Ministry of Health (MoH) programme in Karakalpakstan, Uzbekistan, a region with a high burden of MDR-TB, patient loss from treatment (LFT) remains high despite adherence support strategies. While certain factors associated with LFT have been identified, there is limited understanding of why some patients are able to adhere to treatment while others are not. We conducted a qualitative study to explore patients' experiences with MDR-TB treatment, with the aim of providing insight into the barriers and enablers to treatment-taking to inform future strategies of adherence support.
Publisher:
BioMed Central
Issue Date:
28-Jul-2016
URI:
http://hdl.handle.net/10144/618343
DOI:
10.1186/s12879-016-1723-8
PubMed ID:
27465783
Submitted date:
2016-08-03
Language:
en
ISSN:
1471-2334
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorHorter, Sen
dc.contributor.authorStringer, Ben
dc.contributor.authorGreig, Jen
dc.contributor.authorAmangeldiev, Aen
dc.contributor.authorTillashaikhov, MNen
dc.contributor.authorParpieva, Nen
dc.contributor.authorTigay, Zen
dc.contributor.authordu Cros, Pen
dc.date.accessioned2016-08-11T16:16:13Z-
dc.date.available2016-08-11T16:16:13Z-
dc.date.issued2016-07-28-
dc.date.submitted2016-08-03-
dc.identifier.citationWhere there is hope: a qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan. 2016, 16 (1):362 BMC Infect. Dis.en
dc.identifier.issn1471-2334-
dc.identifier.pmid27465783-
dc.identifier.doi10.1186/s12879-016-1723-8-
dc.identifier.urihttp://hdl.handle.net/10144/618343-
dc.description.abstractTreatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Ministry of Health (MoH) programme in Karakalpakstan, Uzbekistan, a region with a high burden of MDR-TB, patient loss from treatment (LFT) remains high despite adherence support strategies. While certain factors associated with LFT have been identified, there is limited understanding of why some patients are able to adhere to treatment while others are not. We conducted a qualitative study to explore patients' experiences with MDR-TB treatment, with the aim of providing insight into the barriers and enablers to treatment-taking to inform future strategies of adherence support.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to BMC Infectious Diseasesen
dc.titleWhere There is Hope: A Qualitative Study Examining Patients' Adherence to Multi-Drug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistanen
dc.identifier.journalBMC Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.